The FAVOR V AMI Trial
Functional and Angiography-Derived Strain Guided Multi-Vessel/Lesion Revascularization Strategy in Patients With Acute ST-Segment Elevation Myocardial Infarction (FAVOR V AMI)
- ST-Segment Elevation Myocardial Infarction
- Multivessel Coronary Artery Disease
- Percutaneous Coronary Intervention
At a glance
- Phase
- Phase not stated
- Study type
- Interventional
- Sponsor
- China National Center for Cardiovascular Diseases
- Enrolment target
- 5,000
- Started
- 17 January 2023
- Main results due
- 30 June 2028
- Study sites
- 1
- Registry updated
- 24 September 2026
Can you take part?
- Aged 18 years and over.
- Open to any sex.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Inclusion Criteria: * General inclusion 1. Age ≥18 years 2. STEMI ≤30d 3. Successful primary PCI of all culprit lesion(s) responsible for the STEMI (visually-assessed residual stenosis \<30% in stent-treated lesions or \<50% in DCB-treated or PTCA-treated lesions, with TIMI-3 flow in all treated vessels) 4. No MACE event between the index PCI and the staged randomized procedure 5. Able to understand the trial design and provide written informed consent * Angiographic inclusion: 1. The presence of at least 1 non-culprit lesion with DS% 50%-90% in any non-infarct related artery with RVD ≥2.5 mm by visual assessment 2. Non-culprit lesions are potentially eligible for PCI Note: All lesions in the infarct related arteries with DS ≥70% and RVD ≥2.5 mm by visual assessment must be successfully treated either during the index primary PCI or the staged procedure prior to randomization Note: There may also be 1 or more NCL with DS% \>90% (including a CTO) as long as there is at least 1 NCL with DS% 50%-90% as above. Any such lesions in which PCI is intended must be treated successfully either during the index primary PCI or the staged procedure prior to randomization. Exclusion Criteria: * General exclusion 1. Cardiogenic shock or refractory hypotension (Killip IV) 2. On pressors or use of or need for intra-aortic balloon pump or other mechanical circulatory support devices 3. Intubated 4. Prior thrombolytic therapy for this admission 5. Cockcroft-Gault-calculated CrCl \<30 ml/kg 6. Pregnant or woman of child-bearing potential 7. Life expectancy less than 1 year for non-cardiac causes 8. Allergy to iodine-containing contrast agents which cannot be adequately premedicated 9. Unable to tolerate DAPT for at least 6 months 10. Prior CABG or planned CABG 11. Any planned surgery within 6 months 12. Any condition that may interfere with any follow-up procedures (e.g. dementia, drug use) * Angiographic exclusion 1. Poor angiographic image quality precluding vessel contour detection or with suboptimal contrast opacification, branch ostium cannot be shown clearly, severe overlap in the stenosed segment or severe tortuosity of any interrogated vessel deemed not amenable to μQFR or RWS measurement 2. Unable to judge culprit lesion or infarct-related artery according to current evidence
What this study is about
In the sponsor’s own words, from the registry.
The FAVOR V AMI study is a prospective, multicenter, blinded, randomized, sham-controlled trial comparing the long-term clinical outcomes of the "Functional and Angiography-derived Strain inTegration (FAST)" technique (next-generation quantitative flow ratio \[μQFR\] and radial wall strain \[RWS\]) guided percutaneous coronary intervention (PCI) strategy, with standard treatment strategy, in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel coronary disease (MVD).
Study sites(1)
Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing
Beijing, Beijing Municipality, China
Recruiting
Showing 1 of 1 sites. 1 of the 1 site on this study is recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT05669222. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me